vs
CROWN CRAFTS INC（CRWS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是CROWN CRAFTS INC的1.5倍（$30.3M vs $20.7M），CROWN CRAFTS INC净利率更高（7.3% vs -221.3%，领先228.6%），REGENXBIO Inc.同比增速更快（43.0% vs -11.3%），CROWN CRAFTS INC自由现金流更多（$2.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -6.7%）
皇冠工艺品公司是一家美国上市企业，总部位于路易斯安那州冈萨雷斯，主营婴幼儿及青少年消费品的设计、营销与分销业务，公司股票在纳斯达克资本市场挂牌交易，股票代码为CRWS。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CRWS vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.5倍
$20.7M
营收增速更快
RGNX
高出54.3%
-11.3%
净利率更高
CRWS
高出228.6%
-221.3%
自由现金流更多
CRWS
多$55.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-6.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.7M | $30.3M |
| 净利润 | $1.5M | $-67.1M |
| 毛利率 | 23.5% | — |
| 营业利润率 | -0.5% | -190.0% |
| 净利率 | 7.3% | -221.3% |
| 营收同比 | -11.3% | 43.0% |
| 净利润同比 | 69.1% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRWSRGNX
| Q4 25 | $20.7M | $30.3M | ||
| Q3 25 | $23.7M | $29.7M | ||
| Q2 25 | $15.5M | $21.4M | ||
| Q1 25 | $23.2M | $89.0M | ||
| Q4 24 | $23.4M | $21.2M | ||
| Q3 24 | $24.5M | $24.2M | ||
| Q2 24 | $16.2M | $22.3M | ||
| Q1 24 | — | $15.6M |
净利润CRWSRGNX
| Q4 25 | $1.5M | $-67.1M | ||
| Q3 25 | $1.2M | $-61.9M | ||
| Q2 25 | $-1.1M | $-70.9M | ||
| Q1 25 | $-10.8M | $6.1M | ||
| Q4 24 | $893.0K | $-51.2M | ||
| Q3 24 | $860.0K | $-59.6M | ||
| Q2 24 | $-322.0K | $-53.0M | ||
| Q1 24 | — | $-63.3M |
毛利率CRWSRGNX
| Q4 25 | 23.5% | — | ||
| Q3 25 | 27.7% | — | ||
| Q2 25 | 22.7% | — | ||
| Q1 25 | 18.3% | — | ||
| Q4 24 | 26.1% | 70.2% | ||
| Q3 24 | 28.4% | 48.8% | ||
| Q2 24 | 24.5% | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CRWSRGNX
| Q4 25 | -0.5% | -190.0% | ||
| Q3 25 | 7.9% | -176.3% | ||
| Q2 25 | -7.7% | -296.3% | ||
| Q1 25 | -60.7% | 13.6% | ||
| Q4 24 | 7.3% | -242.1% | ||
| Q3 24 | 6.2% | -256.6% | ||
| Q2 24 | -1.8% | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率CRWSRGNX
| Q4 25 | 7.3% | -221.3% | ||
| Q3 25 | 4.9% | -208.3% | ||
| Q2 25 | -7.1% | -331.8% | ||
| Q1 25 | -46.4% | 6.8% | ||
| Q4 24 | 3.8% | -241.3% | ||
| Q3 24 | 3.5% | -246.3% | ||
| Q2 24 | -2.0% | -237.7% | ||
| Q1 24 | — | -405.4% |
每股收益（稀释后）CRWSRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | $-0.10 | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | $-0.03 | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $39.2M | $102.7M |
| 总资产 | $76.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRWSRGNX
| Q4 25 | $2.4M | $230.1M | ||
| Q3 25 | $810.0K | $274.2M | ||
| Q2 25 | $227.0K | $323.3M | ||
| Q1 25 | $521.0K | $267.9M | ||
| Q4 24 | $1.1M | $234.7M | ||
| Q3 24 | $2.0M | $255.5M | ||
| Q2 24 | $1.1M | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益CRWSRGNX
| Q4 25 | $39.2M | $102.7M | ||
| Q3 25 | $38.4M | $161.5M | ||
| Q2 25 | $37.9M | $213.7M | ||
| Q1 25 | $39.6M | $274.2M | ||
| Q4 24 | $51.1M | $259.7M | ||
| Q3 24 | $50.8M | $301.4M | ||
| Q2 24 | $50.7M | $348.3M | ||
| Q1 24 | — | $390.7M |
总资产CRWSRGNX
| Q4 25 | $76.1M | $453.0M | ||
| Q3 25 | $77.5M | $525.2M | ||
| Q2 25 | $76.0M | $581.0M | ||
| Q1 25 | $81.2M | $490.9M | ||
| Q4 24 | $98.7M | $466.0M | ||
| Q3 24 | $99.3M | $519.1M | ||
| Q2 24 | $76.4M | $569.4M | ||
| Q1 24 | — | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $2.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 11.3% | -174.0% |
| 资本支出强度资本支出/营收 | 1.7% | 1.7% |
| 现金转化率经营现金流/净利润 | 1.78× | — |
| 过去12个月自由现金流最近4个季度 | $9.1M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CRWSRGNX
| Q4 25 | $2.7M | $-52.3M | ||
| Q3 25 | $-845.0K | $-56.0M | ||
| Q2 25 | $5.2M | $-49.3M | ||
| Q1 25 | $2.8M | $33.6M | ||
| Q4 24 | $-36.0K | $-31.6M | ||
| Q3 24 | $-983.0K | $-40.5M | ||
| Q2 24 | $8.0M | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流CRWSRGNX
| Q4 25 | $2.3M | $-52.8M | ||
| Q3 25 | $-1.0M | $-56.5M | ||
| Q2 25 | $5.2M | $-49.7M | ||
| Q1 25 | $2.6M | $32.6M | ||
| Q4 24 | $-220.0K | $-32.7M | ||
| Q3 24 | $-1.2M | $-40.9M | ||
| Q2 24 | $7.7M | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率CRWSRGNX
| Q4 25 | 11.3% | -174.0% | ||
| Q3 25 | -4.3% | -189.9% | ||
| Q2 25 | 33.4% | -232.8% | ||
| Q1 25 | 11.3% | 36.6% | ||
| Q4 24 | -0.9% | -154.2% | ||
| Q3 24 | -4.8% | -168.9% | ||
| Q2 24 | 47.7% | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度CRWSRGNX
| Q4 25 | 1.7% | 1.7% | ||
| Q3 25 | 0.7% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 0.9% | 1.2% | ||
| Q4 24 | 0.8% | 5.1% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 1.8% | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率CRWSRGNX
| Q4 25 | 1.78× | — | ||
| Q3 25 | -0.73× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | -0.04× | — | ||
| Q3 24 | -1.14× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRWS
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
